HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

E Feist Selected Research

tocilizumab (atlizumab)

5/2011Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


E Feist Research Topics

Disease

6Rheumatoid Arthritis
02/2014 - 05/2007
4Autoimmune Diseases (Autoimmune Disease)
04/2013 - 09/2000
4Myositis (Idiopathic Inflammatory Myopathies)
05/2008 - 09/2000
3Infections
04/2013 - 01/2000
2Systemic Lupus Erythematosus (Libman-Sacks Disease)
09/2000 - 01/2000
1Psoriasis (Pustulosis Palmaris et Plantaris)
12/2017
1Diffuse Scleroderma (Progressive Systemic Sclerosis)
11/2014
1Synovitis
02/2014
1Tenosynovitis
02/2014
1Tuberculosis (Tuberculoses)
04/2013
1Inflammation (Inflammations)
04/2013
1Hepatitis B
04/2013
1Systemic Vasculitis
02/2013
1Necrosis
05/2011
1Progressive Multifocal Leukoencephalopathy
09/2010
1Adult-Onset Still's Disease
02/2010
1Ulcerative Colitis
12/2009
1Crohn Disease (Crohn's Disease)
12/2009
1Glomerulonephritis
06/2009
1Non-Hodgkin Lymphoma (Lymphosarcoma)
06/2009
1Vasculitis (Vasculitides)
06/2009
1Dermatomyositis (Dermatopolymyositis)
01/2008
1Polymyositis
01/2008
1Uveitis
01/2008
1Lymphoma (Lymphomas)
12/2007
1Carcinoma (Carcinomatosis)
01/2007
1Connective Tissue Diseases (Connective Tissue Disease)
01/2007
1Cryopyrin-Associated Periodic Syndromes
08/2005
1Neonatal Systemic lupus erythematosus
09/2000
1Congenital heart block
09/2000
1Communicable Diseases (Infectious Diseases)
01/2000
1Sepsis (Septicemia)
01/2000

Drug/Important Bio-Agent (IBA)

7AutoantibodiesIBA
04/2013 - 09/2000
5Rituximab (Mabthera)FDA Link
11/2014 - 12/2007
4AntibodiesIBA
12/2009 - 04/2003
3Tumor Necrosis Factor InhibitorsIBA
02/2013 - 09/2010
3AntigensIBA
12/2009 - 05/2007
3Proteasome Endopeptidase Complex (Proteasome)IBA
05/2008 - 09/2000
2Immunoglobulin G (IgG)IBA
09/2010 - 12/2009
1apremilastIBA
12/2017
1secukinumabIBA
12/2017
1Antirheumatic Agents (DMARD)IBA
05/2011
1Rheumatoid FactorIBA
05/2011
1tocilizumab (atlizumab)FDA Link
05/2011
1InterleukinsIBA
05/2011
1Monoclonal AntibodiesIBA
09/2010
1Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
02/2010
1Messenger RNA (mRNA)IBA
12/2009
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
12/2009
1AutoantigensIBA
12/2009
1GlucocorticoidsIBA
06/2009
1Complement System Proteins (Complement)IBA
06/2009
1CryoglobulinsIBA
06/2009
1Mycophenolic Acid (Cellcept)FDA LinkGeneric
01/2008
1Methotrexate (Mexate)FDA LinkGeneric
01/2008
1Pharmaceutical PreparationsIBA
01/2008
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2008
1Infliximab (Remicade)FDA Link
01/2008
1Peptides (Polypeptides)IBA
05/2007
1Proteins (Proteins, Gene)FDA Link
05/2007
1Interleukin-1 Receptors (Interleukin 1 Receptor)IBA
08/2005
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
01/2000
1E-SelectinIBA
01/2000
1Lipopolysaccharide ReceptorsIBA
01/2000
1SelectinsIBA
01/2000

Therapy/Procedure

5Therapeutics
11/2014 - 01/2000
1Precision Medicine
02/2013
1Contraindications
09/2010
1Lasers (Laser)
12/2009